Human CD229/SLAMF3 Antibody
Human CD229/SLAMF3 Antibody Summary
Accession # Q9HBG7
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
CD229, also known as Ly9 and SLAMF3, is a 120 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family (1). Mature human CD229 consists of a 407 amino acid (aa) extracellular domain (ECD) with two Ig‑like V-set and two Ig‑like truncated C2-set domains. It also shows a 22 aa transmembrane segment, and a 179 aa cytoplasmic domain with two immunoreceptor tyrosine-based switch motifs ITSMs (2, 3). The ECD of human CD229 shares 57%‑59% aa sequence identity with mouse and rat CD229. Within the first two Ig‑like domains that are common to all SLAM proteins, human CD229 shares 24%‑39% aa sequence identity with human 2B4, BLAME, CD2F-10, CD84, CRACC, NTB-A, and SLAM. Alternate splicing generates two additional isoforms that lack the juxtamembrane Ig‑like domain or short cytoplasmic region (2). CD229 is expressed on T and B cells, thymocytes, and more weakly on NK cells (2‑6). Homophilic binding between CD229 molecules is mediated by the N-terminal Ig‑like domain (7). Human and mouse CD229 exhibit cross-species binding (7). Antigen stimulation of lymphocytes induces CD229 clustering to sites of T cell - B cell contact (7). Two tyrosines in the cytoplasmic domain are required for association of CD229 with the adaptor proteins AP-2 (μ2 chain) and GRB-2 and both are required for CD229 internalization (8, 9). In addition, there are two ITSMs which mediate phosphorylation-dependent CD229 association with SAP and SHP-2 (10). These four tyrosine-containing motifs are intact in the described CD229 splice variants. CD229 knockout mice show minimally impaired immune responses, suggesting functional redundancy with other molecules (11).
- Bhat, R. et al. (2006) J. Leukoc. Biol. 79:417.
- de la Fuente, M.A. et al. (2001) Blood 97:3513.
- Sandrin, M.S. et al. (1992) J. Immunol. 149:1636.
- Romero, X. et al. (2004) Tissue Antigens 64:132.
- Hogarth, P.M. et al. (1980) Immunogenetics 11:65.
- Mathieson, B.J. et al. (1980) J. Immunol. 125:2127.
- Romero, X. et al. (2005) J. Immunol. 174:7033.
- Del Valle, J.M. et al. (2003) J. Biol. Chem. 278:17430.
- Martin, M. et al. (2005) J. Immunol. 174:5977.
- Sayos, J. et al. (2001) Blood 97:3867.
- Graham, D.B. et al. (2006) J. Immunol. 176:291.
Citation for Human CD229/SLAMF3 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
The extracellular interactome of the human adenovirus family reveals diverse strategies for immunomodulation
Nat Commun, 2016-05-05;7(0):11473.
Sample Types: Cell Lysates, Whole Cells
Applications: Flow Cytometry, Western Blot
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CD229/SLAMF3 Antibody
There are currently no reviews for this product. Be the first to review Human CD229/SLAMF3 Antibody and earn rewards!
Have you used Human CD229/SLAMF3 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image